FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
Portfolio Pulse from Vandana Singh
The FDA approved ImmunityBio Inc's Anktiva for BCG-unresponsive non-muscle invasive bladder cancer, marking a significant advancement in immunotherapy. The approval follows a previous FDA complete response letter and is based on promising clinical results, including a 62% complete response rate. Anktiva, a first-in-class IL-15 agonist, is expected to be available in the U.S. by mid-May 2024. Following the announcement, IBRX shares rose by 4.65% to $5.17.
April 23, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FDA approval of Anktiva for bladder cancer represents a major milestone for ImmunityBio, indicating a positive outlook for the company's product pipeline and market position.
The FDA approval of Anktiva is a critical event for ImmunityBio, showcasing the company's ability to navigate regulatory hurdles and bring innovative treatments to market. The positive clinical trial results and the drug's designation as a first-in-class therapy underscore its potential impact on the treatment of bladder cancer. The immediate positive reaction in stock price reflects investor confidence in the drug's market potential and ImmunityBio's growth prospects. The long-term impact on the stock will depend on the commercial success of Anktiva, but the approval itself is a significant positive development.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100